Protalix Biotherapeutics (NYSEAMERICAN:PLX) posted its earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03), Fidelity Earnings reports. The company had revenue of $2.01 million during the quarter, compared to analyst estimates of $7.00 million.
Protalix Biotherapeutics traded down $0.01, reaching $0.49, during trading hours on Friday, MarketBeat Ratings reports. 628,300 shares of the stock were exchanged, compared to its average volume of 712,780. Protalix Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $0.92.
PLX has been the subject of a number of recent research reports. HC Wainwright set a $5.00 price target on Protalix Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, June 11th. Zacks Investment Research raised Protalix Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 12th.
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.
Featured Article: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.